Основная статистика
| LEI | 549300CTZMJMPH28WN39 |
| CIK | 1399529 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Dicerna Pharmaceuticals Inc
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 14, 2022 |
DRNA / Dicerna Pharmaceuticals Inc / BALYASNY ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Dicerna Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36281 Dicerna Pharmaceuticals, Inc. (Exact name of registrant as specifi |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition EXHIBIT (a)(5)(C) Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition Bagsv?rd, Denmark, 28 December 2021 ? Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals (Dicerna), announced on 18 November 2021, has been completed. |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
BYLAWS DICERNA PHARMACEUTICALS, INC. * * * * * ARTICLE 1 Exhibit 3.2 BYLAWS OF DICERNA PHARMACEUTICALS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) DICERNA PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) NNUS NEW RESEARCH, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Va |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 S-8 POS 1 d250577ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. 333-253563 Registration No. 333-236892 Registration No. 333-233149 Registration No. 333-223648 Registration No. 333-210071 Registration No. 333-193795 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTR |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 POS AM 1 d277734dposam.htm POS AM As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. 333-224989 Registration No. 333-223778 Registration No. 333-214082 Registration No. 333-202687 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-224989 POST-EFFECTIVE AMENDMENT NO |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 S-8 POS 1 d250577ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. 333-253563 Registration No. 333-236892 Registration No. 333-233149 Registration No. 333-223648 Registration No. 333-210071 Registration No. 333-193795 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTR |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2021 Dicerna Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other Jurisdiction of Incorporation) (Co |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class o |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. |
|
| December 28, 2021 |
As filed with the Securities and Exchange Commission on December 28, 2021 POSASR 1 d276463dposasr.htm POSASR As filed with the Securities and Exchange Commission on December 28, 2021 Registration No. 333-234572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-234572 UNDER THE SECURITIES ACT OF 1933 Dicerna Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its C |
|
| December 28, 2021 |
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition Exhibit 99.1 Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition LEXINGTON, Mass.?(BUSINESS WIRE)? Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk?s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding |
|
| December 28, 2021 |
CERTIFICATE OF INCORPORATION DICERNA PHARMACEUTICALS, INC. December 28, 2021 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF DICERNA PHARMACEUTICALS, INC. December 28, 2021 FIRST: The name of the corporation is Dicerna Pharmaceuticals, Inc. (the ?Corporation?). SECOND: The address of its registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at s |
|
| December 27, 2021 |
SC TO-T/A 1 dp164121sctota2.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) DICERNA PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) NNUS NEW RESEARCH, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of |
|
| December 27, 2021 |
Exhibit (a)(5)(L) Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna December 25, 2021 08:00 AM Eastern Standard Time LEXINGTON, Mass. |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class o |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class o |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) DICERNA PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) NNUS NEW RESEARCH, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Va |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class o |
|
| December 3, 2021 |
DRNA / Dicerna Pharmaceuticals Inc / BALYASNY ASSET MANAGEMENT LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Dicerna Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 253031108 (CUSIP Number) November 23, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ |
|
| November 24, 2021 |
Exhibit 99.1 Article Summarizing Interview with Doulas M. Fambrough III, Ph.D., President and Chief Executive Officer of Dicerna, published by MedWatch on November 24, 2021. Link: https://medwatch.com/News/PharmaBiotech/article13496333.ece Dicerna CEO explains how a desire to expand collaborations turned into a potential acquisition Novo Nordisk?s possible billion-dollar takeover of US-based Dicer |
|
| November 24, 2021 |
Exhibit (d)(6) AMENDMENT This Amendment shall become effective as of 14 August 2019 (the ?Effective Date?). |
|
| November 24, 2021 |
MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (d)(5) MUTUAL CONFIDENTIALITY AGREEMENT This mutual confidentiality agreement (the ?Agreement?) shall become effective as of August 14, 2018 (the ?Effective Date?). |
|
| November 24, 2021 |
CONFIDENTIAL DISCLOSURE AGREEMENT Exhibit (d)(7) CONFIDENTIAL DISCLOSURE AGREEMENT THIS CONFIDENTIAL DISCLOSURE AGREEMENT (the ?Agreement?) is made as of the last dated signature below (the ?Effective Date?) by and between Dicerna Pharmaceuticals Inc. |
|
| November 24, 2021 |
Exhibit (a)(1)(C) Offer To Purchase For Cash All Outstanding Shares of Common Stock of DICERNA PHARMACEUTICALS, INC. |
|
| November 24, 2021 |
[Remainder of page intentionally blank] Exhibit (d)(2) CONFIDENTIAL October 27, 2021 Novo Nordisk A/S Novo Alle 1 2880 Bagsvaerd Denmark Re: Confidentiality Agreement Novo Nordisk (referred to herein as ?you or your?) has requested certain Evaluation Material (as defined below) from Dicerna Pharmaceuticals, Inc. |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 2530 |
|
| November 24, 2021 |
Exhibit (a)(1)(b) LETTER OF TRANSMITTAL To accompany certificates of common stock, $0. |
|
| November 24, 2021 |
Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of DICERNA PHARMACEUTICALS, INC. |
|
| November 24, 2021 |
Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of DICERNA PHARMACEUTICALS, INC. |
|
| November 24, 2021 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 DICERNA PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) NNUS NEW RESEARCH, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Sh |
|
| November 18, 2021 |
Exhibit 99.2 Novo Nordisk LinkedIn Post, November 18, 2021 Embedded Video Transcript: Marcus Schindler, Executive Vice President and Chief Scientific Officer: I?m really excited to announce today that we?re acquiring Dicerna ? a leading company in RNAi therapeutics. We?re building on our existing, very successful co-creation partnership and taking it to the next level to unlock the full potential |
|
| November 18, 2021 |
Dicerna Employee Frequently Asked Questions (FAQs) INTERNAL ONLY Exhibit 99.2 Dicerna Internal ONLY 11/18/21 Dicerna Employee Frequently Asked Questions (FAQs) INTERNAL ONLY What was announced? Novo Nordisk and Dicerna announced a definitive agreement pursuant to which Novo Nordisk will acquire Dicerna for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna?s closing price on November 17, 2021. The tra |
|
| November 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Dicerna Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other Jurisdiction of Incorporation) (Co |
|
| November 18, 2021 |
Dicerna Letter to Employees first used on November 18, 2021 Exhibit 99.1 Dicerna Letter to Employees first used on November 18, 2021 From: Douglas M. Fambrough Subject: Big news! Novo Nordisk to acquire Dicerna CONFIDENTIAL- INTERNAL ONLY November 18, 2021 Dear Dicerna Team, I am pleased to announce that Dicerna has signed an agreement to be acquired by Novo Nordisk for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a p |
|
| November 18, 2021 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: NOVO NORDISK A/S, a Danish aktieselskab; NNUS NEW RESEARCH, INC., a Delaware corporation; and DICERNA PHARMACEUTICALS, INC., a Delaware corporation Dated as of November 17, 2021 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the Company 6 2.2 Effect of the Merger 6 |
|
| November 18, 2021 |
Dicerna LinkedIn Post, posted on November 18, 2021 Exhibit 99.3 Dicerna LinkedIn Post, posted on November 18, 2021 Hyperlink: https://investors.dicerna.com/news-releases/news-release-details/novo-nordisk-acquire-dicerna Dicerna Tweet, posted on November 18, 2021 |
|
| November 18, 2021 |
SC14D9C 1 d260606dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Dicerna Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or ot |
|
| November 18, 2021 |
Exhibit 99.1 Novo Nordisk to Acquire Dicerna ? Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna?s Proprietary GalXC? Technology Platform ? LEXINGTON, Mass., Nov. 18 2021 ? Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biop |
|
| November 18, 2021 |
SC TO-C 1 dp161916sctoc.htm FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 DICERNA PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) NNUS NEW RESEARCH, INC. a wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Dicerna Pharmaceuticals, Inc. (Name of Subject Company) Dicerna Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 2530 |
|
| November 18, 2021 |
Dicerna “Retweet” of Novo post, posted on November 18, 2021 Exhibit 99.4 Dicerna ?Retweet? of Novo post, posted on November 18, 2021 Embedded Video Transcript: I?m really excited to announce today that we are aquiring Dicerna ? a leading company in RNAi therapeutics. We?re building on our existing, very successful co-creation partnership and taking it to the next level to unlock the full potential of RNAi technology across all our therapy areas. With the R |
|
| November 18, 2021 |
Form of Key Stakeholder Letter, first sent on November 18, 2021 Exhibit 99.5 Form of Key Stakeholder Letter, first sent on November 18, 2021 [Date] Dear [valued partner/ name of advisory board member/ name of leader/ supplier/ vendor]: As we announced in a press release earlier today, Dicerna is pleased to share that we have entered into an agreement to become part of Novo Nordisk. Novo Nordisk, a world leader in developing and commercializing medicines to tre |
|
| November 18, 2021 |
Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform Exhibit 99.1 Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform Bagsv?rd, Denmark, 18 November 2021 ? Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna?s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk?s existing rese |
|
| November 18, 2021 |
LinkedIn post by Ling Zeng, Chief Legal Officer and Secretary of Dicerna, posted November 18, 2021 Exhibit 99.6 LinkedIn post by Ling Zeng, Chief Legal Officer and Secretary of Dicerna, posted November 18, 2021 Congratulations to the team! https://investors.dicerna.com/news-releases/news-release-details/novo-nordisk-acquire-dicerna |
|
| November 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2021 |
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update ? Reported Positive Top-Line Data From Pivotal PHYOX?2 Clinical Trial of Nedosiran Investigational GalXC? RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) ? ? Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) ? ? Company Plans to Unveil First GalXC-Plus? Extrahepatic Target in Early 2022 ? ? Cash Runway Extends Into 2025 ? ? Company to Host Conference Call Today at 8:30 a. |
|
| August 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commi |
|
| August 9, 2021 |
EX-99.1 2 drna20210809xex991.htm EX-99.1 Exhibit 99.1 Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria – – Announced U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) App |
|
| August 6, 2021 |
Exhibit 99.1 Dicerna Reports Positive Top-Line Results From PHYOX?2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria ? Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants ? ? Nedosiran Was Generally We |
|
| August 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2021 |
Topline Data Presentation Investigation of Nedosiran for the Treatment of Primary Hyperoxaluria Type 1 and Type 2 August 5, 2021 Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. |
|
| June 4, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2021 |
Exhibit 10.2 AMENDMENT NO. 1 TO TRANSITION AND SEPARATION AGREEMENT This Amendment No. 1 to Transition and Separation Agreement (the ?Amendment?) amends the Transition and Separation Agreement between Dicerna Pharmaceuticals, Inc (the ?Company?) and Ralf Rosskamp (?you?) with a letter date of April 16, 2020 and an ?Effective Date? of April 28, 2020 (the ?Agreement?). This Amendment shall be effect |
|
| May 6, 2021 |
Exhibit 10.1 Royalty Purchase Agreement By and Between Dicerna Pharmaceuticals, inc. and RPI 2019 Intermediate Finance Trust Dated as of April 8, 2021 Table of Contents Page Article 1 DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Definitions 1 Section 1.2 Certain Interpretations 1 Section 1.3 Headings 1 Article 2 PURCHASE, SALE AND ASSIGNMENT OF THE ROYALTY 1 Section 2.1 Closing 1 Section |
|
| May 6, 2021 |
Exhibit 10.3 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the ?Amendment?) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the ?Company?) and John B. Green (the ?Executive?) dated as of February 21, 2020 (the ?Agreement?). WHEREAS, the original Agreement contained a clerical error in describing the |
|
| May 6, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234572 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed maximum aggregate offering price Amount of registration fee(1) Common Stock, par value $0.0001 per share $200,000,000 $21,820 (1) Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended, or the Secu |
|
| May 6, 2021 |
Exhibit 10.8 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the ?Amendment?) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the ?Company?) and Regina Paglia (the ?Executive?) dated as of February 21, 2020 (the ?Agreement?). WHEREAS, the original Agreement contained a clerical error in describing the |
|
| May 6, 2021 |
EX-10.5 7 drna20210331xex1005.htm EX-10.5 Exhibit 10.5 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and James B. Weissman (the “Executive”) dated as of February 21, 2020 (the “Agreement”). WHEREAS, the original Agreemen |
|
| May 6, 2021 |
Exhibit 10.6 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the ?Amendment?) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the ?Company?) and Ralf Rosskamp (the ?Executive?) dated as of February 21, 2020 (the ?Agreement?). WHEREAS, the original Agreement contained a clerical error in describing the |
|
| May 6, 2021 |
Exhibit 10.7 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the ?Amendment?) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the ?Company?) and Robert Ciappenelli (the ?Executive?) dated as of February 21, 2020 (the ?Agreement?). WHEREAS, the original Agreement contained a clerical error in describin |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| May 6, 2021 |
EX-99.1 2 drna20210506xex991.htm EX-99.1 Exhibit 99.1 Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update – Announced Sale of OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million; Extends Cash Runway Into 2024 – – Earned $25 Million Milestone Payment in Connection With Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combinati |
|
| May 6, 2021 |
EX-10.4 6 drna20210331xex1004.htm EX-10.4 Exhibit 10.4 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and Bob D. Brown (the “Executive”) dated as of February 21, 2020 (the “Agreement”). WHEREAS, the original Agreement con |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commissi |
|
| May 6, 2021 |
Sales Agreement, dated as of May 6, 2021, between the Registrant and Cowen and Company, LLC. EX-10.9 11 drna20210331xex1009.htm EX-10.9 Exhibit 10.9 DICERNA PHARMACEUTICALS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT May 6, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 20, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commis |
|
| March 12, 2021 |
Amended and Restated Bylaws of Dicerna Pharmaceuticals, Inc. Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF DICERNA PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) (Approved and Adopted as of March 11, 2021) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Dicerna Pharmaceuticals, Inc. (the ?Corporation?) in the State of Delaware shall be as set forth in the Certificate of Incorporation of the Corporation, as amended from time to time (th |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commi |
|
| March 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commis |
|
| March 2, 2021 |
drna20210302xex9901 Corporate Overview Discovery to Commercialization RNAi Platform March 2021 Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. |
|
| February 26, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 26, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| February 26, 2021 |
Exhibit 21.1 SUBSIDIARIES OF DICERNA PHARMACEUTICALS, INC. Name Jurisdiction of Incorporation Dicerna Security Corporation Delaware Dicerna EU Limited England Dicerna Ireland Limited Ireland Dicerna Germany GmbH Germany |
|
| February 25, 2021 |
Exhibit 99.1 Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update – 2020 Highlights Include: Enrollment Completion of Pivotal PHYOX™2 Trial of Nedosiran for Primary Hyperoxaluria; Positive RG6346 Phase 1 Data for HBV; Positive Nedosiran Multidose Data from PHYOX3 Trial; First IND From Lilly Collaboration – – Company Announces Internal Clinical Development Program for T |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Co |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13D-1(K)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13D-1(K)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 12, 2021 |
EX-99.1 Corporate Overview Discovery to Commercialization RNAi Platform January 2021 Exhibit 99.1 Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ material |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2021 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Com |
|
| December 14, 2020 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| November 5, 2020 |
Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2016 Inducement Plan. EX-10.4 5 drna20200930ex104.htm EX-10.4 Exhibit 10.4 DICERNA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2016 INDUCEMENT PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT THIS STOCK UNIT AWARD AGREEMENT (this “Agreement”) is dated as of [ , 2020] by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and [ ] (the “Participant”). WITNESSETH WHEREAS, pursuant to the Dicern |
|
| November 5, 2020 |
EX-10.3 4 drna20200930ex103.htm EX-10.3 Exhibit 10.3 DICERNA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2014 PERFORMANCE INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT THIS STOCK UNIT AWARD AGREEMENT (this “Agreement”) is dated as of [ , 2020] by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and [ ] (the “Participant”). WITNESSETH WHEREAS, pursuant to |
|
| November 5, 2020 |
Employment Agreement by and between the Company and EX-10.1 2 drna20200930ex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) made this 23rd day of July, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Shreeram Aradhye, M.D. (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires t |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Com |
|
| November 5, 2020 |
EX-99.1 2 drna20201105ex991.htm EX-99.1 Exhibit 99.1 Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update – Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 – – Company Reported $609.9 Million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2020 – – Management to Host Conference Call Today |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| November 5, 2020 |
Employment Agreement by and between the Company and Exhibit 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) made this 15th day of September 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Ling Zeng (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms set forth |
|
| October 22, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 22, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Com |
|
| October 22, 2020 |
Exhibit 99.1 Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH) – All Participants Receiving Nedosiran, Regardless of Subtype, Achieved Normalization or Near-Normalization of Urinary Oxalate, a Key PH Measure, by Day 180 in Ongoing, Open-Label Trial – – Nedosiran Was Generally Well Tolerated With No |
|
| September 16, 2020 |
EX-99.1 2 drna20200916ex991.htm EX-99.1 Exhibit 99.1 Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary – Biopharmaceutical Industry Veteran Brings Expertise in Global Drug Development and Corporate Governance – LEXINGTON, Mass., Sept. 16, 2020 - Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interfere |
|
| September 16, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (C |
|
| September 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (C |
|
| September 14, 2020 |
dicernacorporatepresenta Corporate Overview Maximizing the Impact of RNAi on Medicine September 2020 Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. |
|
| September 4, 2020 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Douglas Fambrough, Douglas W. |
|
| August 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Comm |
|
| August 13, 2020 |
drna20200812xexx991 Exhibit 99.1 Corporate Overview Maximizing the Impact of RNAi on Medicine August 2020 Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ |
|
| August 11, 2020 |
EX-99.1 2 d949173dex991.htm EX-99.1 Exhibit 99.1 Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update – Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 – – Company Reported $669.2 Million in Cash, Cash Equivalents and Marketable Securities as of June 30, 2020 – – Management to Host Virtual R&D Day Event Today a |
|
| August 11, 2020 |
EX-99.4 5 d949173dex994.htm EX-99.4 Exhibit 99.4 Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer – Dr. Aradhye Brings to Dicerna More Than 20 Years of Successfully Leading Global Teams in Developing Diverse Portfolios of Innovative Medicines– LEXINGTON, Mass., Aug. 5, 2020 — Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” o |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Com |
|
| August 11, 2020 |
EX-99.3 Dicerna 2020 Virtual R&D Update: Nedosiran, RG6346 and Going Beyond GalXC™ August 6, 2020 Exhibit 99.3 Forward-Looking Statements This presentation includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking sta |
|
| August 11, 2020 |
EX-99.2 Exhibit 99.2 Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues – In the Ongoing Phase 1 Proof-of-Concept Trial Multidose Group, RG6346 1.5, 3.0 and 6.0 mg/kg Dosing Cohorts Reached Mean HBsAg Reduction From Baseline of 1.3 |
|
| August 6, 2020 |
EX-10.1 2 drna20200630ex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT (Revised) EMPLOYMENT AGREEMENT (“Agreement”) made this February 21, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Regina DeTore Paglia (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desire |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| August 6, 2020 |
Exhibit 10.5 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Second Amendment to Collaboration and License Agreement This Second Amendment to Collaboration and License Agreement (“Amendment”), effective on June 22, 2020 (“Amendment Effective Date”), is by and |
|
| August 6, 2020 |
EX-10.6 7 drna20200630ex106.htm EX-10.6 Exhibit 10.6 75 Hayden Avenue Lexington, Massachusetts (the “Building”) FIRST AMENDMENT EXECUTION DATE: July 1, 2020 LANDLORD: HCP/King 75 Hayden LLC, a Delaware limited liability company TENANT: Dicerna Pharmaceuticals, Inc., a Delaware corporation EXISTING PREMISES: Areas on the first (1st) floor, the fourth (4th) floor, the Penthouse and the roof of the B |
|
| August 6, 2020 |
EX-99.2 3 d11361dex992.htm EX-99.2 Exhibit 99.2 Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues – In the Ongoing Phase 1 Proof-of-Concept Trial Multidose Group, RG6346 1.5, 3.0 and 6.0 mg/kg Dosing Cohorts Reached Mean HBsAg Red |
|
| August 6, 2020 |
EX-99.3 Dicerna 2020 Virtual R&D Update: Nedosiran, RG6346 and Going Beyond GalXC™ August 6, 2020 Exhibit 99.3 Forward-Looking Statements This presentation includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking sta |
|
| August 6, 2020 |
EX-99.1 2 d11361dex991.htm EX-99.1 Exhibit 99.1 Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update – Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 – – Company Reported $669.2 Million in Cash, Cash Equivalents and Marketable Securities as of June 30, 2020 – – Management to Host Virtual R&D Day Event Today at |
|
| August 6, 2020 |
Exhibit 10.3 EXECUTION VERSION CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. PATENT CROSS-LICENSE AGREEMENT between DICERNA PHARMACEUTICALS, INC. and ALNYLAM PHARMACEUTICALS, INC. April 3, 2020 TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATIONS 1 2. |
|
| August 6, 2020 |
Exhibit 10.4 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. First Amendment to Collaboration and License Agreement This First Amendment to Collaboration and License Agreement (“Amendment”), effective on May 22, 2020 (“Amendment Effective Date”), is by and be |
|
| August 6, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (C |
|
| August 6, 2020 |
Exhibit 10.2 EXECUTION VERSION CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT between DICERNA PHARMACEUTICALS, INC. and ALNYLAM PHARMACEUTICALS, INC. April 3, 2020 || TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATIO |
|
| August 6, 2020 |
Exhibit 10.07 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is entered into effective as of July 1, 2020 (the “Second Amendment Date”), by and between WESTERN OFFICE PORTFOLIO PROPERTY OWNER LLC, a Delaware limited liability company (“Landlord”), and DICERNA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS: A.Landlord, as l |
|
| August 6, 2020 |
EX-99.4 Exhibit 99.4 Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer – Dr. Aradhye Brings to Dicerna More Than 20 Years of Successfully Leading Global Teams in Developing Diverse Portfolios of Innovative Medicines– LEXINGTON, Mass., Aug. 5, 2020 — Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading deve |
|
| July 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of Incorporation) (Commiss |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of Incorporation) (Commis |
|
| June 18, 2020 |
Exhibit 99.1 Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria LEXINGTON, Mass., June 18, 2020 – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug |
|
| June 17, 2020 |
DICERNA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 99.1 DICERNA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or off |
|
| June 17, 2020 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of Incorporation) (Commis |
|
| May 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commissi |
|
| May 8, 2020 |
dicernacorporatepresenta Corporate Overview May 2020 © 2020 DICERNA Forward-looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. |
|
| May 7, 2020 |
Employment Agreement by and between the Company and Douglas Pagán, dated as of May 26, 2020. Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) made this May 26th, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Douglas Pagán (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms |
|
| May 7, 2020 |
Transition Agreement dated as of April 16, 2020, by and between the Company and Ralf Rosskamp. EX-10.1 2 rosskampralf-transitio.htm EX-10.1 Exhibit 10.1 April 16, 2020 Ralf Rosskamp 270 3rd Street, Apt 701 Cambridge, MA 02142 Re: Transition and Separation Agreement Dear Ralf: Dicerna Pharmaceuticals, Inc. (the “Company”) greatly appreciates your dedication and service to the Company. You and I have discussed our mutual interest in bringing your employment to an end and doing so in a manner |
|
| May 7, 2020 |
Exhibit 99.2 Dicerna To Appoint Douglas Pagán Chief Financial Officer – Mr. Pagán Brings to Dicerna More Than 20 Years of Biopharmaceutical Financial Management Experience – LEXINGTON, Mass., May 7, 2020 - Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas |
|
| May 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commissi |
|
| May 7, 2020 |
EX-99.1 3 drna20200507ex991.htm EX-99.1 Exhibit 99.1 Dicerna Announces First Quarter 2020 Financial Results and Provides a Business Update — Company Continues to Advance Ongoing Nedosiran, DCR-A1AT and RG6346 Clinical Trials — — Company Well Capitalized With $706.9 Million in Cash, Cash Equivalents and Marketable Securities as of March 31, 2020 – — Management to Host Conference Call Today at 4:30 |
|
| April 22, 2020 |
DRNA / Dicerna Pharmaceuticals, Inc. DEF 14A - - DEF 14A DEF 14A 1 drna2020xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Co |
|
| April 22, 2020 |
DRNA / Dicerna Pharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 20, 2020 |
8-K 1 drna20200420x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdi |
|
| April 6, 2020 |
8-K 1 drna20200406x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdic |
|
| April 6, 2020 |
Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Dicerna Pharmaceuticals, Inc. Media: Amy Trevvett, Dicerna Pharmaceuticals, Inc. +1 617-612-6253 [email protected] Investors: Lauren Stival, Stern Investor Relations, Inc. +1 212-362-1200 [email protected] Alnylam and Dicerna Form RNAi Therap |
|
| April 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commis |
|
| April 1, 2020 |
dicernacorporatepresenta Corporate Overview April 2020 © 2020 DICERNA Forward-looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. |
|
| March 31, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 drna20200331x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdi |
|
| March 31, 2020 |
Exhibit 99.1 Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan - Preliminary Interim Data Show Normalization or Near-Normalization of Oxalate Levels in First Subset of Four Patients - - Nedosiran Multidose Data to Be Presented at OxalEurope Meeting Now Rescheduled to June 16, 2020 - LEXINGTON, Mass., |
|
| March 26, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commi |
|
| March 26, 2020 |
Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic Exhibit 99.1 Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic LEXINGTON, Mass., March 26, 2020 - Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of its response to the COVID-19 pandemic and an update on business continuity and clinical development miles |
|
| March 4, 2020 |
DRNA / Dicerna Pharmaceuticals, Inc. S-8 - - S-8 S-8 1 forms-8.htm S-8 As filed with the Securities and Exchange Commission on March 4, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-5993609 (State or other jurisdiction of incorporatio |
|
| February 28, 2020 |
Exhibit 10.30 EMPLOYMENT AGREEMENT (Revised) EMPLOYMENT AGREEMENT (“Agreement”) made this February 21, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and James B. Weissman (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms |
|
| February 28, 2020 |
Exhibit 10.29 EMPLOYMENT AGREEMENT (Revised) EMPLOYMENT AGREEMENT (“Agreement”) made this February 21, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and John Green (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms set for |
|
| February 28, 2020 |
Exhibit 10.46 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXECUTION COPY Confidential Collaboration and License Agreement This Agreement, dated as of October 30, 2019, is entered into by and between F. Hoffmann-La Roche Ltd with an office and place of bus |
|
| February 28, 2020 |
Exhibit 10.32 February 21, 2020 Douglas M. Fambrough, III, Ph.D. Re: Amendment to Employment Agreement Dear Mr. Fambrough: This letter agreement (the “Amendment”) by and between yourself and Dicerna Pharmaceuticals, Inc. (the “Company”) is intended to amend that certain Amended and Restated Employment Agreement between you and the Company, dated July 8, 2016 (the “Agreement”). This Amendment is ef |
|
| February 28, 2020 |
Exhibit 21.1 SUBSIDIARIES OF DICERNA PHARMACEUTICALS, INC. Name Jurisdiction of Incorporation Dicerna Security Corporation Delaware Dicerna EU Limited England Dicerna Ireland Limited Ireland Dicerna Germany GmbH Germany |
|
| February 28, 2020 |
Employment Agreement dated as of June 19, 2019, by and between the Company and Robert Ciappenelli. EX-10.54 13 exhibit1054.htm EXHIBIT 10.54 Exhibit 10.54 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT ("Agreement") made this 3rd of June 2019 (the "Effective Date") between Dicerna Pharmaceuticals, Inc., a Delaware corporation ("Company"), on the one hand and Robert Ciappenelli (the "Executive") on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be em |
|
| February 28, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| February 28, 2020 |
Exhibit 10.33 EMPLOYMENT AGREEMENT (Revised) EMPLOYMENT AGREEMENT (“Agreement”) made this February 21, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Ralf Rosskamp (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms set |
|
| February 28, 2020 |
EX-4.1 2 exhibit41.htm EXHIBIT 4.1 Exhibit 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Dicerna Pharmaceuticals, Inc. (“Dicerna,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its |
|
| February 28, 2020 |
Transition Agreement dated as of February 27, 2020, by and between the Company and John B. Green. Exhibit 10.56 February 26, 2020 John B. Green 91 Elliott Drive Lowell, MA 01852 Re: Transition Agreement Dear Jack: Dicerna Pharmaceuticals, Inc. (the “Company”) greatly appreciates your dedication and service to the Company. You and I have discussed our mutual interest in bringing your employment to an end and doing so in a manner that provides a smooth transition for both you and the Company. Th |
|
| February 28, 2020 |
Share Issuance Agreement, dated November 15, 2019, by and between the Company and Novo Nordisk A/S. Exhibit 10.48 EXECUTION VERSION SHARE ISSUANCE AGREEMENT THIS SHARE ISSUANCE AGREEMENT (this “Agreement”), is made as of November 15, 2019, by and between Novo Nordisk A/S, a public limited liability company (the “Share Acquiror”), and Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, concurrently with the entering into of this Agreement, the Company and the Share Acq |
|
| February 28, 2020 |
Exhibit 10.55 EMPLOYMENT AGREEMENT (Revised) EMPLOYMENT AGREEMENT (“Agreement”) made this February 21, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Robert Ciappenelli (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms |
|
| February 28, 2020 |
Exhibit 10.31 EMPLOYMENT AGREEMENT (Revised) EMPLOYMENT AGREEMENT (“Agreement”) made this February 21, 2020 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc., a Delaware corporation (“Company”), on the one hand and Bob D. Brown (the “Executive”) on the other hand. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company, on terms set f |
|
| February 28, 2020 |
Exhibit 10.47 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT between NOVO NORDISK A/S and DICERNA PHARMACEUTICALS, INC. NOVEMBER 15, 2019 1. DEFINITIONS AND INTERPRETATIONS 1 2. TARGET SELECTION AND VALIDATION 24 2.1 Targe |
|
| February 28, 2020 |
Lease Agreement between the Company and HCP/King 75 Hayden LLC, dated as of January 14, 2020. Exhibit 10.53 75 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS 02421 LEASE SUMMARY SHEET Execution Date: January 14, 2020 Tenant: DICERNA PHARMACEUTICALS, INC., a Delaware corporation Tenant’s Mailing Address: 33 Hayden Avenue Lexington, MA 02421 Attn: David W. Miller, PhD, SVP Landlord: HCP/KING 75 HAYDEN LLC, a Delaware limited liability company Building: 75 Hayden Avenue, Lexington, Massachusetts 0242 |
|
| February 28, 2020 |
Exhibit 10.52 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “First Amendment”) is entered into effective as of February 4, 2020 (the “First Amendment Date”), by and between WESTERN OFFICE PORTFOLIO PROPERTY OWNER LLC, a Delaware limited liability company (“Landlord”), and DICERNA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS: A.Landlord, as l |
|
| February 27, 2020 |
Exhibit 99.1 Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - Company Achieves Multiple Clinical and Corporate Development Milestones in 2019, Advancing Core Pipeline Candidates; Expanding and Progressing Existing Collaborative Programs; and Establishing New, High-Value Collaborations With Roche and Novo Nordisk A/S - - Anticipated 2020 Milesto |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Co |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
DRNA / Dicerna Pharmaceuticals, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2020 |
DRNA / Dicerna Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2020 |
SC 13G/A 1 bridger-drna123119a2.htm SCHEDULE 13G HOLDINGS REPORT AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2019 (Date of Event W |
|
| February 14, 2020 |
DRNA / Dicerna Pharmaceuticals, Inc. / RTW INVESTMENTS, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 10, 2020 |
8-K 1 drna20200210x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other juris |
|
| February 6, 2020 |
8-K 1 drna20200206x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other juris |
|
| January 13, 2020 |
8-K 1 d867296d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2020 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdictio |
|
| January 13, 2020 |
EX-99.1 January 2020 Corporate Overview Exhibit 99.1 This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forwa |
|
| January 13, 2020 |
Form of Restricted Stock Unit Grant Notice EX-10.2 Exhibit 10.2 DICERNA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2014 PERFORMANCE INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Dicerna Pharmaceuticals, Inc. (the “Company”), pursuant to its Amended and Restated 2014 Performance Incentive Plan (the “Plan”), hereby awards to you, the Participant, the number of Restricted Stock Units (“RSUs”) set forth below (“Award”). This Award is subje |
|
| January 13, 2020 |
Form of Restricted Stock Unit Award Agreement EX-10.1 2 d867296dex101.htm EX-10.1 Exhibit 10.1 DICERNA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2014 PERFORMANCE INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT THIS STOCK UNIT AWARD AGREEMENT (this “Agreement”) is dated as of [ , 2020] by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and [ ] (the “Participant”). W I T N E S S E T H WHEREAS, pursua |
|
| December 16, 2019 |
Entry into a Material Definitive Agreement, Other Events 8-K 1 drna-201912168k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other juri |
|
| December 6, 2019 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| November 21, 2019 |
SC 13D/A 1 d806631dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4) Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par |
|
| November 18, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 drna-201911158k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other juri |
|
| November 7, 2019 |
DRNA / Dicerna Pharmaceuticals, Inc. S-3ASR - - S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 7, 2019 Registration No. |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| November 7, 2019 |
LEASE AGREEMENT BETWEEN WESTERN OFFICE PORTFOLIO PROPERTY OWNER LLC, AS LANDLORD AND DICERNA PHARMACEUTICALS, INC. |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2019 DICERNA PHARMACEUTICALS, INC. |
|
| November 7, 2019 |
Exhibit 99.1 Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress — Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S. — — $312.7 Million in Cash, Cas |
|
| October 31, 2019 |
8-K 1 drna-2019118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdi |
|
| September 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of Incorporation) (C |
|
| September 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of Incorporation) (C |
|
| August 8, 2019 |
DRNA / Dicerna Pharmaceuticals, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on August 8, 2019 Registration No. |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2019 DICERNA PHARMACEUTICALS, INC. |
|
| August 8, 2019 |
Exhibit 99.1 Dicerna™ Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Strengthened Management with Senior Hires Across Medical Affairs, Commercial, Regulatory, and Patient Advocacy and Patient Services - - Initiated dosing in PHYOX™3 Roll-over Extension Study for the Treatment of Primary Hyperoxaluria (PH) - - Received Breakthrough Therapy Designation for DCR-PHXC for |
|
| August 8, 2019 |
10-Q 1 drna-20190630x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| June 24, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of incorporation) (Commis |
|
| May 31, 2019 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240. |
|
| May 10, 2019 |
Lease Agreement between the Company and Hayden Office Trust, dated as of January 2, 2019. 33 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS Lease Dated January 2, 2019 THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building known as, and with an address at, 33 Hayden Avenue, Lexington, Massachusetts 02421. |
|
| May 10, 2019 |
EX-10.1.1 3 drnaex1011.htm EXHIBIT 10.1.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the “First Amendment”) dated as of this 6th day of March, 2019 by and between HAYDEN OFFICE TRUST under Declaration of Trust dated August 24, 1977, as the same may have been amended (“Landlord”), and DICERNA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS By Lease dated January 2, 2 |
|
| May 10, 2019 |
Amended and Restated 2014 Performance Incentive Plan, as amended and restated on May 7, 2019. DICERNA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2014 PERFORMANCE INCENTIVE PLAN (AS AMENDED AND RESTATED ON MAY 7, 2019) 1. PURPOSE OF PLAN The purpose of this Dicerna Pharmaceuticals, Inc. Amended and Restated 2014 Performance Incentive Plan (this “Plan”) of Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase s |
|
| May 10, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 drna-20190510x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2019 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdictio |
|
| May 9, 2019 |
Exhibit 99.1 Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update — Initiated Screening of Participants to Enroll in the PHYOX™2 Phase 2 Pivotal Trial of DCR-PHXC for the Treatment of Primary Hyperoxaluria (PH) and Announced Updated Data from Ongoing PHYOX1 Phase 1 of DCR-PHXC – — Dosed First Healthy Volunteer in Phase 1 Clinical Trial of DCR-HBVS for T |
|
| April 26, 2019 |
DRNA / Dicerna Pharmaceuticals, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2019 |
DEF 14A 1 drna-20190424xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 13, 2019 |
EX-10.35 3 exhibit1035.htm EXHIBIT 10.35 Exhibit 10.35 SHARE ISSUANCE AGREEMENT THIS SHARE ISSUANCE AGREEMENT (this “Agreement”), is made as of October 22, 2018, by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (the “Share Acquiror”), and Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, concurrently with the entering into of this Agreement, the Co |
|
| March 13, 2019 |
EX-10.34 2 exhibit1034.htm EXHIBIT 10.34 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(3) and 240.24b-2 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between Alexion Pharma Holding Unlimited Company Dicerna Pharmaceuticals Inc. and Dicerna Cayman DATED OCTOBER 22, 2018 COLLABORATIVE RESEARCH AND |
|
| March 13, 2019 |
EX-10.36 4 exhibit1036.htm EXHIBIT 10.36 EXECUTION VERSION ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(3) and 240.24b-2 Exhibit 10.36 COLLABORATION AND LICENSE AGREEMENT between ELI LILLY AND COMPANY and DICERNA PHARMACEUTICALS INC. together with DICERNA CAYMAN October 25, 2018 ***Text Omitted |
|
| March 13, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| March 13, 2019 |
EX-21.1 7 exhibit211.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARIES OF DICERNA PHARMACEUTICALS, INC. Name Jurisdiction of Incorporation Dicerna Security Corporation Delaware Dicerna Cayman Cayman Dicerna EU Limited England Dicerna Ireland Limited Ireland |
|
| March 13, 2019 |
EX-10.37 5 exhibit1037.htm EXHIBIT 10.37 SHARE ISSUANCE AGREEMENT THIS SHARE ISSUANCE AGREEMENT (this “Agreement”), is made as of October 25, 2018, by and between Eli Lilly and Company, an Indiana corporation (the “Share Acquiror”), and Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, concurrently with the entering into of this Agreement, the Company and the Share Ac |
|
| March 13, 2019 |
***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(3) and 240.24b-2 Contract number: 43085381 ADDITIONAL TARGET AGREEMENT between Boehringer Ingelheim International GmbH Binger Strasse 173, 55216 Ingelheim am Rhein, Germany ("BOEHRINGER") VAT-ID-No.: DE 811138149 and Dicerna Pharmaceuticals Inc. 87 C |
|
| March 11, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2019 DICERNA PHARMACEUTICALS, INC. |
|
| March 11, 2019 |
Exhibit 99.1 DicernaTM Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update - 2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering - - Company’s Robust Cash Position Provides Funds Beyond 2020 to Fuel Pipeline Adv |
|
| February 14, 2019 |
DRNA / Dicerna Pharmaceuticals, Inc. / RTW INVESTMENTS, LLC Passive Investment SC 13G/A 1 sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2019 |
DRNA / Dicerna Pharmaceuticals, Inc. / Cormorant Asset Management, LLC Passive Investment SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 14, 2019 |
JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) Exhibit 1 JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 14, 2019 |
DRNA / Dicerna Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 drna13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 253031108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 25, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2019 DICERNA PHARMACEUTICALS, INC. |
|
| January 8, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 2, 2019 DICERNA PHARMACEUTICALS, INC. |
|
| January 4, 2019 |
Entry into a Material Definitive Agreement, Results of Operations and Financial Condition 8-K 1 d639791d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2018 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdictio |
|
| December 20, 2018 |
Exhibit 1 Exhibit 1 EXECUTION VERSION SHARE ISSUANCE AGREEMENT THIS SHARE ISSUANCE AGREEMENT (this “Agreement”), is made as of October 25, 2018, by and between Eli Lilly and Company, an Indiana corporation (the “Share Acquiror”), and Dicerna Pharmaceuticals, Inc. |
|
| December 20, 2018 |
DRNA / Dicerna Pharmaceuticals, Inc. / LILLY ELI & CO - SC 13D Activist Investment SC 13D 1 d660779dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. ) Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 253031108 (CUSIP Number) Copies to: Michael J. Harrington General Counsel Eli Lilly and |
|
| November 7, 2018 |
DRNA / Dicerna Pharmaceuticals, Inc. 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q/A Amendment No. |
|
| November 7, 2018 |
DRNA / Dicerna Pharmaceuticals, Inc. / RA Capital Management, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 253031108 (CUSIP Number) RA Capital Management, LLC 20 Park Plaza, Suite 1200 Boston, MA 02116 Telephone: 617.778.2512 Attn: Peter Kol |
|
| November 5, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2018 DICERNA PHARMACEUTICALS, INC. |
|
| November 5, 2018 |
Exhibit 99.1 Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019 Entered into Strategic Collaborations with Lilly and Alexion to Discover and Develop RNAi Therapies Using Dicerna’s GalXC™ Technology Platform Closed $115.0 Million Financ |
|
| November 5, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 5, 2018 |
DRNA / Dicerna Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 drna-10q20180930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num |
|
| November 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Dicerna Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 253031108 (CUSIP Number) RA Capital Management, LLC 20 Park Plaza, Suite 1200 Boston, MA 02116 Telephone: 617.778.2512 Attn: Peter Kol |
|
| October 29, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2018 DICERNA PHARMACEUTICALS, INC. |
|
| October 24, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 22, 2018 DICERNA PHARMACEUTICALS, INC. |
|
| September 11, 2018 |
EX-1.1 2 d619521dex11.htm EX-1.1 Exhibit 1.1 7,680,492 Shares DICERNA PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT September 6, 2018 CITIGROUP GLOBAL MARKETS INC. LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o CITIGROUP GLOBAL MARKETS INC. 388 Greenwich Street New York, New York 10013 c/o LEERINK PARTNERS LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladie |
|
| September 11, 2018 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 6, 2018 DICERNA PHARMACEUTICALS, INC. |
|
| September 10, 2018 |
7,680,492 Shares Dicerna Pharmaceuticals, Inc. Common Stock $13.02 per share 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224989 PROSPECTUS SUPPLEMENT (To prospectus dated May 31, 2018) 7,680,492 Shares Dicerna Pharmaceuticals, Inc. Common Stock $13.02 per share We are selling 7,680,492 shares of our common stock. We have granted the underwriters an option to purchase up to 1,152,073 additional shares of common stock. Our common stock is li |
|
| September 6, 2018 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 5, 2018 424B5 1 d621198d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224989 The information contained in this preliminary prospectus supplement and the accompanying base prospectus is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospe |
|
| September 5, 2018 |
8-K 1 d619088d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2018 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdictio |
|
| August 17, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2018 DICERNA PHARMACEUTICALS, INC. |
|
| August 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2018 DICERNA PHARMACEUTICALS, INC. |
|
| August 8, 2018 |
EX-99.1 2 d602743dex991.htm EX-99.1 Exhibit 99.1 Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass., August 8, 2018 — Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial |
|
| August 8, 2018 |
EX-10.2 3 drna-ex102180.htm EX-10.2 Exhibit 10.2 CONFIDENTIAL SHARE ISSUANCE AGREEMENT THIS SHARE ISSUANCE AGREEMENT (this “Agreement”), is made as of April 20, 2018, by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Share Acquiror”), and Dicerna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, concurrently with the entering into of this Agreement, t |
|
| August 8, 2018 |
Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 CONFIDENTIAL SETTLEMENT AGREEMENT AND GENERAL RELEASE This Settlement Agreement and General Release (the “Agreement”) is entered into this 18th day of April 2018 (the “Effective Date”) by and among Alnylam Pharmaceutical |
|
| August 8, 2018 |
DRNA / Dicerna Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36281 DICERNA PHARMACEUTICALS, INC. |
|
| June 22, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 d634212d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2018 DICERNA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36281 20-5993609 (State or other jurisdiction of |
